Muthusamy Shanmugam - 11 Feb 2026 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)

Role
HEAD OF R&D, COO-NOVITIUM OPS, Director
Signature
/s/ Muthusamy Shanmugam, by attorney-in-fact Meredith W. Cook
Issuer symbol
ANIP
Transactions as of
11 Feb 2026
Net transactions value
-$220,972
Form type
4
Filing time
13 Feb 2026, 16:06:29 UTC
Previous filing
22 Aug 2025
Next filing
02 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS, Director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE /s/ Muthusamy Shanmugam, by attorney-in-fact Meredith W. Cook 13 Feb 2026 0001870913

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANIP Common Stock Tax liability $220,972 -2,898 -3.1% $76.25 89,940 11 Feb 2026 Direct F1, F2
holding ANIP Common Stock 431,920 11 Feb 2026 Held by Esjay LLC F3
holding ANIP Common Stock 5,000 11 Feb 2026 Held by SS Pharma LLC F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,578 performance stock units, the grant of which was previously reported on April 6, 2023.
F2 Includes 250 shares of ANI Pharmaceuticals, Inc. Common Stock that were acquired under the ANI Pharmaceuticals, Inc. Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c).
F3 The reporting person holds voting and dispositive power over the shares held by Esjay LLC.
F4 The reporting person holds voting and dispositive power over the shares held by SS Pharma LLC.